Nusano and PharmaLogic Partner to Enhance Cancer Treatment Options

Nusano and PharmaLogic's New Supply Agreement

Nusano Inc. and PharmaLogic Holdings Corp. have entered into a strategic supply agreement to offer a more efficient and dependable supply of essential radioisotopes.

This collaboration aims to increase the availability of high-demand radioisotopes that are crucial for new and emerging cancer therapies produced in PharmaLogic's facilities.

Critical Radioisotopes for Cancer Therapies

Radioisotopes play a vital role in the active pharmaceutical ingredients used in innovative cancer treatments. Challenges in the current supply chains have been limiting patient care and clinical advancements.

By joining forces, Nusano will provide on-demand radioisotopes, such as lutetium-177, actinium-225, copper-67, and astatine-211, to PharmaLogic, thereby ensuring a continuous and reliable supply for their various therapeutic applications.

Benefits of the Partnership

This partnership is set to enhance PharmaLogic's ability to meet the needs of their customers by leveraging Nusano's advanced production capabilities.

James Beatty, Vice President of Development and Commercialization for PharmaLogic, emphasizes the importance of such collaborations in maintaining high-quality standards and making advancements in radiopharmaceutical diagnostics and therapies.

Future Plans and Production Goals

Under the agreement, both companies will work collaboratively to determine the production schedule for radioisotopes. They will also review and adjust the supply agreement annually to meet the evolving needs of the radiopharmaceutical industry.

Nusano's CEO, Chris Lowe, highlights that their proprietary production platform enables the production of up to 12 different radioisotopes simultaneously, providing greater flexibility and capacity to meet market demands.

Delivery Timeline and Industry Impact

Nusano plans to start commercial-scale production and delivery of lutetium-177 by Q1 2025 and actinium-225 by H2 2025.

This initiative is set to alleviate existing supply chain pressures, allowing PharmaLogic and its collaborators to concentrate on developing new cancer therapies for patients.

About the Companies

Nusano specializes in stabilizing radiopharmaceutical supply chains through innovative technologies and increased production yields, aiming to benefit researchers, drugmakers, and clinicians.

PharmaLogic is a renowned contract development and manufacturing organization focused on diagnostic imaging and therapeutic radiopharmaceuticals, spearheading advancements in radiopharmaceutical technology.